SESSIONS WILL BE DIVIDED INTO 3 TRACKS PRIOR TO THE EVENT. DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.
THE DAY WILL START WITH NETWORKING AT 08:00 AND CONCLUDE WITH A NETWORKING SESSION FINISHING AT 17:00.
TRENDS
Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practises drive future productivity?
With the ever increasing focus on personalised medicines, what strategies are we putting in place to ensure new drugs hit the 5Rs? Are we maximising clinical data? What does this mean for rare diseases?
How are tech giants and pharma companies collaborating to drive innovation in healthcare? What are the large pharma companies really looking for when it comes to new technologies, and at what stage will they pay for them? Is pharma manufacturing making the most of the digital revolution? Will COVID-19 change all of this?
Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practises drive future productivity?
With the ever increasing focus on personalised medicines, what strategies are we putting in place to ensure new drugs hit the 5Rs? Are we maximising clinical data? What does this mean for rare diseases?
How are tech giants and pharma companies collaborating to drive innovation in healthcare? What are the large pharma companies really looking for when it comes to new technologies, and at what stage will they pay for them? Is pharma manufacturing making the most of the digital revolution? Will COVID-19 change all of this?
The pharma and lifesciences ecosystem was already facing significant opportunities and disruption from technology advances, pricing pressure, digital and new entrants. In a Covid-19 world and with Brexit uncertainty the level of disruption has only been amplified. This panel will explore the disruptive themes and key success factors for companies to navigate our changing environment.
FACILITATED BY
JO PISANI | Strategic Advisor, Non Executive Director and Charity Trustee
PANELLISTS INCLUDE
JOHN DAWSON | Chief Executive Officer | Oxford Biomedica RICHARD TORBETT | Chief Executive Officer | ABPI BRIAN HENRY | Vice President, Global Head of Drug Product Design | Pfizer Worldwide Research and Development
Taking stock: Impact on supply chains in a post Covid world
The COVID 19 virus pandemic has rocked the world to its core. There are likely to be many and far-reaching consequences of this on the Pharmaceutical industry. One aspect that will come under scrutiny is in the area of risk management of Pharmaceutical supply chains. Will we see radical changes in the factors pharma companies consider when making outsourcing decisions? Will they recalculate the balance between working capital and inventory management? Will large companies consider a slowing or even reversal in the trend to outsource API/DP manufacture, with greater investment in internal assets?
FACILITATED BY
STEVE BARR | Vice President Of Business Development | SK pharmteco
Experiences of how we can lead our teams through change when it is imposed upon us
How challenge creates opportunities
How we can harness new ways of working to a more productive future
FACILITATED BY
KATHRYN SIMPSON | Business Consultant | Kathryn Simpson Consulting
PANELLISTS INCLUDE
PRIYA MANDE | Chief Operating Officer | PsiOxus Therapeutics SIMON HIRST | Chief Executive Officer | Sygnature Discovery EMMA SCEATS | Chief Executive | Isogenica MICHELE LESUEUR | Hematology Oncology Business Unit Director | Celgene KIMBERLY SMITH | Head of Global Research and Medical Strategy | ViiV Healthcare
What are we doing differently now that’s better than before? What do we foresee might be future benefits of new ways of working?
FACILITATED BY
TINA FLATAU | Chief Executive Officer | Biopharma Projects
PANELLISTS INCLUDE
FLIC GABBAY | Managing Partner | tranScrip DAVID HAWKINS | Founder and Chief Executive Officer | Remedium Capital HELEN BARKER | Head of Pharmaceutical Development | Reneo Pharma SEAN BREEN | Head Public Private Partnerships and Science Policy | Takeda
Will inshoring ensure the delivery of your products?
Undeniably, COVID-19 has changed how companies approach their global operations, from travel to outsourcing. How will looking closer to home impact the costs versus risk balance and the integrity of your supply chain?
FACILITATED BY
RICHARD WEAVER | Founder and Managing Director | XenoGesis
Communication Strategies – the need for strategic relationships being more important than ever before in our new era.
• Defining a strategic client • Maintaining the strategic relationship • The role of the executive team to engage • Selling up the organization during Covid • Role of technology
FACILITATED BY
STUART NEEDLEMAN | Chief Commercial Officer | Piramal Pharma Solutions
The growing focus on rare diseases and what this means for clinical trials.
FACILITATED BY
RON JORTNER | Managing Director & Trustee | Masthead Biosciences & Cambridge Rare Disease Network
PANELLISTS INCLUDE
PATRICK SHORT | Co-founder and Chief Executive Officer | Sano Genetics VANESSA LEMARIE | Lead, Rare Disease Initiative | Ada Health STEVE ANDERSON | Chief Scientific Officer | Covance NICK SIREAU | Chair and Chief Executive Officer | AKU Society
Respiratory diseases remain a key target for pharma companies. Are we maximising our assets and this as a drug delivery route?
FACILITATED BY
MARK DUMAN | Managing Director & Assessor- Digital Health; BioMedical Catalyst | MD Healthcare Consultants & Innovate UK
PANELLISTS INCLUDE
MARK MILTON-EDWARDS | Head of Health Solutions – Digital Health | TEVA Pharmaceuticals Marianne Veighey | Director, Head of Intelligent Pharmaceuticals | AstraZeneca
Patenting in a pandemic: How can you make your IP future-proof and flexible?
The world of healthcare has changed enormously in the last 12 months. Many companies aren’t letting a crisis go to waste – they are repurposing drugs to treat Covid-19 and rushing to protect potential IP. Overs haven’t been so fortunate – lockdown has prevented them from generating the data needed to secure patents.
Building flexibility into your patent portfolio is more important now than ever. Through case studies, we will discuss:
Options for securing effective IP on repurposed drugs.
Tips for speeding up and slowing down prosecution.
Powers that Governments have to use patented drugs and the enforcement of IP rights for Covid vaccines and treatments.
Securing IP for Covid-related inventions: the balance between patenting for profit and philanthropy.
PANELLISTS INCLUDE
AMANDA SIMONS | Partner, Patent Attorney | J A Kemp LLP GRAHAM LEWIS | Partner, Patent Attorney | J A Kemp LLP
What are the large pharma companies really looking for when it comes to new technologies, and at what stage will they pay for them?
PANELLISTS INCLUDE
JOE DE SOUSA | Senior Leader, Non-Exec Director and Independent Consultant | Melhor Consulting PAUL TUNNAH | Chief Content Officer & Managing Director UK | healthware MARTINO PICARDO | Chairman | Discovery Park
Are we making the most of data and digital technologies for pharma manufacturing?
FACILITATED BY
DAVE TUDOR | Managing Director, Medicines Manufacturing Innovation Centre | CPI
PANELLISTS INCLUDE
JASON LACOMBE | Chief Executive Officer | Veratrak ASHLEY HOWARD | EMEA and Global Strategy, Pharma Group | Applied Materials Pharma JON-PAUL SHERLOCK | Global Technology Strategy Director, MS&T | AstraZeneca
What is the role of technology in healthcare? How are tech giants and pharma companies collaborating to drive innovation in healthcare? Hear from some of the leaders in Pharma R&D and cutting-edge tech companies on how they see the future of innovation in healthcare.
JOHN TSAI | Head of Global Drug Development, Chief Medical Officer | Novartis SIR MENELAS (MENE) PANGALOS | Executive Vice President, BioPharmaceuticals R&D | AstraZeneca FRANCESCO DE RUBERTIS | Co-founder and Partner | Medicxi MIKE REA | Strategic Innovation Advisor and Chief Executive Officer | Nanoform and IDEA Pharma
Covid-19 has meant rapid adoption of digital health across the system. As health and care become digital by default, what should pharma do next? Should they think internally, utilising digital health to improve their own processes; tactically, with digital health offerings for their own brands; or as a strategic partner, supporting health economies to be more sustainable, efficient and resilient? Join us as we discuss the changing landscape?
FACILITATED BY
HASSAN CHAUDHURY | Digital Health Lead | Department for International Trade
PANELLISTS INCLUDE
RACHEL MURPHY | Chief Executive Officer | Difrent MATTHEW CLEMENTE | Vice President, Device Development, Device R&D | Novo Nordisk NAWAL ROY | Chief Executive Officer and Founder | Holmusk ANTHONY DAY | Blockchain Partner, Global Business Services | IBM Ireland Limited
Seeing is believing: Patient focussed manufacturing
The panel will address:
• Solutions by simulation • Reconfiguring patient healthcare through digital technology • Better patient outcomes, lower-cost healthcare, data-driven innovation
FACILITATED BY
JO PISANI | Strategic Advisor, Non Executive Director and Charity Trustee
PANELLISTS INCLUDE
ROMA MAGUIRE | Professor of Digital Health and Care | University of Strathclyde JAGJIT SINGH SRAI | Head, Centre for International Manufacturing, Institute for Manufacturing | University of Cambridge GEORGE CROOKS | Chief Executive Officer | Digital Health & Care Institute
